GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2007

Amaxa and Promega Ally to Simplify Monitoring of Cell Signaling Events

  • Amaxa and Promega are working together to provide broader access to monitor cell-signaling events in difficult-to-transfect cells including stem cells, cancer cells, and primary cells. Integrating their tools in luminescence-based assays and transfection methodologies will simplify transfection of reporter genes and assay development in these cell types, according to the companies.

    Amaxa’s Nucleofector® technology is used for transfection in applications involving more biologically relevant mammalian systems such as primary cells and stem cells. “With the Nucleofector technology, transfection efficiencies of up to 95% using DNA and 99% using siRNA oligonucleotides can be achieved in difficult-to-transfect cells,” states Rainer Christine, co-founder and CEO, Amaxa. “Thus, the combination of Promega and Amaxa technologies will enable researchers to obtain much more significant results with physiologically relevant cells rather than more artificial cell lines.”

    Promega says that its luciferase reporter gene vectors and assay reagents are sensitive bioluminescent tools to monitor cell signaling events and provide the dynamic range in reporter assay technologies. “Luciferase reporters are routinely used to monitor gene expression and are ideal tools for high-throughput screening, RNAi-mediated gene regulation, and detection of cellular metabolism and viability,” explains John Watson, director of cellular analysis, Promega. “The combination of Promega’s luciferase products and Amaxa’s technology will enable the generation of stable cell lines and bioluminescent cell-based assays even for primary cells.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?